The case for & against
Bull & Bear analysis
Bullish
Dynavax Technologies Corporation (NASDAQ: DVAX) is a biopharmaceutical company that specializes in developing and commercializing innovative vaccines targeting infectious diseases. They are well-established in the adult hepatitis B vaccine market with their flagship product, HEPLISAV-B. The company is also advancing a diverse pipeline that includes candidates for shingles and pandemic influenza, putting them in a strong position within a market that is projected for substantial growth due to increasing vaccine demand and public health initiatives.
Bull says
- ↑Q2 2025 HEPLISAV-B revenue reached $92M, up 31% YoY.
- ↑Adult hepatitis B market share rose to 46%, aiming for 60% by 2030.
- ↑Completed $200M share repurchase, reflecting disciplined capital allocation.
- ↑Z1018 shingles vaccine program readouts expected in upcoming quarters.
- ↑ACIP universal recommendation expands hepatitis B vaccination addressable population.
- ↑Gross margin improved to 85%, adjusted EBITDA growth and $648M cash balance.
Bear says
- ↓Ongoing FDA review of additional dosing could delay market launch.
- ↓Q1 2025 net loss of $96M and rising R&D expenses pose cash risks.
- ↓Intensifying competition may pressure pricing and limit market share gains.
- ↓Shingles vaccine success hinges on long-term data at six to 12 months.
- ↓Seasonal demand fluctuations risk uneven quarterly sales performance.
- ↓Operating costs rising faster than revenue may pressure future margins.
Investment themes with DVAX
Biotech↑ +0.07%
Genetic and drug innovations driving medical breakthroughs
ABBV · AMGN · TMO
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 09-07-2026neutral
Transcript signals
Bull points
- we believe there's an opportunity to develop an improved shingles vaccine given the challenging tolerability profile of the current market-leading product.
- In the second quarter, we initiated a randomized, active-controlled dose escalation, multi-center phase 1-2 trial to evaluate the safety, tolerability, and immunogenicity of Z1018 compared to Shingrix.
- We anticipate reporting top line immunogenicity and safety data in the second half of 2025.
Bear points
- Yeah, a single dose I think is going to be challenging. I think it's going to be challenging for everybody With respect to reactogenicity, you know, we're seeing fine reactogenicity even with our higher dose of CPG-1018.
- in the previous study, we compared one dose of the Z1018 with one dose of Shingrix, and they were the same. It was the second dose in which things seemed to improve more for Shingrix than it did for us.
- in the previous study, We compared one dose of the Z1018 with one dose of Shingrix, and they were the same. It was the second dose in which things seemed to improve more for Shingrix than it did for us.
Read full transcript analysis ›